{"id":"c5bc5b03-fac1-4555-a5aa-70a2428f26b5","name":"Paradromics","slug":"paradromics","description":"Paradromics is an Austin-based neurotechnology company developing the [Connexus BCI](/models/connexus-bci), a high data-rate fully implantable brain-computer interface for restoring speech and computer control in people with severe motor impairment. First human implantation completed June 2026 at University of Michigan Health as part of the FDA-approved Connect-One clinical trial.","status":null,"founded":null,"hq":"Austin, Texas, USA","hqLat":null,"hqLng":null,"hqGeocodedAt":null,"hqAddress":null,"hqPrecision":null,"website":"paradromics.com","fundingTotal":"33000000","type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://paradromics.com/news/paradromics-receives-fda-approval-for-the-connect-one-clinical-study-with-the-connexus-brain-computer-interface/","title":"Paradromics Receives FDA Approval for the Connect-One Clinical Study with the Connexus BCI","sourceName":"Paradromics"}],"keyFacts":[{"label":"FDA","value":"IDE approved + Breakthrough Device"},{"label":"Funding","value":"$33M Series A (Prime Movers Lab)"},{"label":"Data rate","value":"200+ bits/sec"},{"label":"Product","value":"Connexus BCI (fully implantable)"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-08-08T22:30:25.339Z","updatedAt":"2026-08-08T22:41:07.609Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/paradromics","url":"https://registry.deploy.report/companies/paradromics","name":"Paradromics","description":"Paradromics is an Austin-based neurotechnology company developing the [Connexus BCI](/models/connexus-bci), a high data-rate fully implantable brain-computer interface for restoring speech and computer control in people with severe motor impairment. First human implantation completed June 2026 at University of Michigan Health as part of the FDA-approved Connect-One clinical trial.","identifier":"c5bc5b03-fac1-4555-a5aa-70a2428f26b5","address":"Austin, Texas, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}